Table 2.
Baseline clinical characteristics of all study subjects after IPW.
| After IPW | ||||||
| Variables | SR group (n = 657) | RFA group (n = 653) | Transarterial group (n = 745) | IPW SD + | IPW SD ++ | IPW SD +++ |
| Age, n (%) | –0.0247 | 0.0277 | 0.0524 | |||
| ≥65 yrs | 218.341 (33.59) | 209.022 (31.14) | 244.353 (32.43) | |||
| <65 yrs | 431.667 (66.41) | 462.22 (68.86) | 509.115 (67.57) | |||
| Gender, male, n (%) | 479.937 (73.84) | 493.054 (73.45) | 546.844 (72.58) | –0.0284 | –0.0198 | 0.0087 |
| BMI (kg/m2)∗ | 24.2 ± 2.9 | 24.2 ± 3.3 | 24.2 ± 3.3 | –0.0110 | 0.0018 | 0.0128 |
| HTN, presence, n (%) | 242.147 (37.25) | 248.235 (36.98) | 262.128 (34.79) | –0.0513 | –0.0457 | 0.0056 |
| DM, presence, n (%) | 151.447 (23.3) | 154.005 (22.94) | 181.207 (24.05) | 0.0177 | 0.0261 | 0.0084 |
| Etiology, n (%) | ||||||
| HBV | 410.41 (63.14) | 440.4 (65.61) | 489.276 (64.94) | 0.0375 | –0.0141 | –0.0516 |
| HCV | 95.011 (14.62) | 82.323 (12.26) | 93.78 (12.45) | –0.0635 | 0.0055 | 0.0690 |
| Others (reference) | ||||||
| Albumin (g/dL)∗ | 4.1 ± 0.5 | 4.1 ± 0.5 | 4.1 ± 0.5 | –0.0110 | –0.0818 | –0.0722 |
| Bilirubin (mg/dL) | 0.9 ± 0.4 | 0.9 ± 0.4 | 0.9 ± 0.5 | 0.0211 | –0.0009 | –0.0228 |
| PT, INR∗ | 1.1 ± 0.1 | 1.1 ± 0.1 | 1.1 ± 0.1 | –0.0213 | –0.0268 | –0.0067 |
| PLT (×103/uL)∗ | 138.2 ± 52.9 | 133.9 ± 61.5 | 136.7 ± 64.9 | –0.0261 | 0.0431 | 0.0745 |
| AFP (ng/dL)∗ | 247.3 ± 928.5 | 632.8 ± 2374.1 | 268.3 ± 3271 | 0.0088 | –0.1275 | –0.2139 |
| Tumor size, n (%) | 0.0032 | 0.0143 | 0.0112 | |||
| <2 cm | 314.788 (48.43) | 321.319 (47.87) | 366.081 (48.59) | |||
| ≤2 cm and ≤3cm | 335.219 (51.57) | 349.923 (52.13) | 387.388 (51.41) | |||
| FU duration (month)† | 50 (1–106) | 52 (3–107) | 48 (1–107) | |||